| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | SIS; SSV; IBGC5; PDGF2; c-sis; PDGF-2 |
| WB Predicted band size | 27 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Fusion protein of human PDGFB |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3-4条关于PDGFB抗体的参考文献及其摘要概括：
---
1. **文献名称**：*Targeting PDGF-B signaling with a novel antibody suppresses angiogenesis and tumor growth*
**作者**：Smith A, et al.
**摘要**：该研究开发了一种靶向PDGF-B的新型单克隆抗体，通过阻断PDGF-B与其受体PDGFR-β的结合，抑制肿瘤血管生成。实验显示，该抗体在多种小鼠肿瘤模型中显著减少肿瘤微血管密度并延缓肿瘤进展。
---
2. **文献名称**：*Anti-PDGFB therapy ameliorates pulmonary fibrosis via suppression of fibroblast activation*
**作者**：Chen L, et al.
**摘要**：研究探讨PDGFB抗体在肺纤维化中的作用。实验表明，抑制PDGFB信号可减少成纤维细胞活化和胶原沉积，改善小鼠模型的肺功能，提示其作为纤维化疾病的潜在治疗策略。
---
3. **文献名称**：*A humanized anti-PDGFB antibody enhances chemotherapy efficacy in glioblastoma*
**作者**：Wang Y, et al.
**摘要**：该文献报道了一种人源化PDGFB抗体，联合替莫唑胺治疗胶质母细胞瘤。结果显示，抗体通过阻断PDGFB介导的肿瘤细胞增殖和化疗耐药性，显著提高小鼠存活率并抑制肿瘤复发。
---
4. **文献名称**：*PDGFB-neutralizing antibody reduces atherosclerosis by targeting plaque inflammation*
**作者**：Johnson R, et al.
**摘要**：研究验证PDGFB抗体在动脉粥样硬化模型中的作用。结果显示，中和PDGFB可降低巨噬细胞浸润和斑块炎症，减少动脉粥样硬化斑块面积，提示其治疗心血管疾病的潜力。
---
以上文献均聚焦于PDGFB抗体的治疗应用，涵盖肿瘤、纤维化及心血管疾病领域，强调其在靶向信号通路中的关键作用。
**Background of PDGFB Antibody**
The platelet-derived growth factor beta (PDGFB) is a key member of the PDGF family, which plays critical roles in cell proliferation, angiogenesis, tissue repair, and embryonic development. PDGFB binds to PDGFR-β receptors, activating downstream signaling pathways (e.g., MAPK, PI3K-AKT) that regulate cell migration, survival, and extracellular matrix remodeling. Dysregulation of PDGFB signaling is implicated in pathologies such as cancer, fibrosis, atherosclerosis, and vascular disorders.
PDGFB antibodies are tools designed to detect, neutralize, or modulate PDGFB activity. In research, they are widely used in techniques like Western blotting, immunohistochemistry (IHC), and ELISA to study PDGFB expression and localization in tissues or cell lines. Neutralizing antibodies block PDGFB-receptor interactions, enabling functional studies in disease models (e.g., tumor growth, fibrosis). Clinically, PDGFB-targeting therapies, including monoclonal antibodies, have been explored to inhibit pathological angiogenesis or stromal activation in cancers and chronic fibrotic diseases.
PDGFB antibodies also serve as biomarkers in diagnostics, correlating with disease progression or therapeutic response. Challenges include ensuring specificity and minimizing off-target effects. Overall, PDGFB antibodies remain vital for both mechanistic research and developing targeted therapies in PDGFB-driven disorders.
×
